Feng M, Prieto MC, Navar LG. Nebivolol-induced vasodilation of renal afferent arterioles involves ␤3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol 303: F775-F782, 2012. First published June 6, 2012 doi:10.1152/ajprenal.00233.2012.-Nebivolol is a ␤1-adrenergic blocker that also elicits renal vasodilation and increases the glomerular filtration rate (GFR). However, its direct actions on the renal microvasculature and vasodilator mechanism have not been established. We used the in vitro blood-perfused juxtamedullary nephron technique to determine the vasodilator effects of nebivolol and to test the hypothesis that nebivolol induces vasodilation of renal afferent arterioles via an nitric oxide synthase (NOS)/nitric oxide (NO)/soluble guanylate cyclase (sGC)/cGMP pathway and the afferent arteriolar vasodilation effect may be mediated through the release of NO by activation of NOS via a ␤3-adrenoceptor-dependent mechanism. Juxtamedullary nephrons were superfused with nebivolol either alone or combined with the sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) or the NOS inhibitor N -nitro-Larginine (L-NNA) or the ␤-blockers metoprolol (␤1), butoxamine (␤2), and SR59230A (␤ 3). Nebivolol (100 mol/l) markedly increased afferent and efferent arteriolar diameters by 18.9 Ϯ 3.0 and 15.8 Ϯ 1.8%. Pretreatment with L-NNA (1,000 mol/l) or ODQ (10 mol/l) decreased afferent vasodilator diameters and prevented the vasodilator effects of nebivolol (2.0 Ϯ 0.2 and 2.4 Ϯ 0.6%). Metoprolol did not elicit significant changes in afferent vasodilator diameters and did not prevent the effects of nebivolol to vasodilate afferent arterioles. However, treatment with SR59230A, but not butoxamine, markedly attenuated the vasodilation responses to nebivolol. Using a monoclonal antibody to ␤ 3-receptors revealed predominant immunostaining on vascular and glomerular endothelial cells. These data indicate that nebivolol vasodilates both afferent and efferent arterioles and that the afferent vasodilator effect is via a mechanism that is independent of ␤ 1-receptors but is predominantly mediated via a NOS/NO/sGC/ cGMP-dependent mechanisms initiated by activation of endothelial ␤ 3-receptors.
NEBIVOLOL IS A NOVEL ANTIHYPERTENSIVE drug (23, 49) that exhibits a higher degree of selectivity for ␤ 1 -adrenergic receptors compared with other ␤-blockers used in clinical practice (5, 34) . Nebivolol reduces heart rate, blood pressure, and peripheral and coronary vascular resistance and lowers left ventricular afterload and preload and elicits vasodilation (5, 27, 39) . In kidney studies (22) , nebivolol at a dose of 1 mg/kg increased renal plasma flow, glomerular filtration rate (GFR), urine flow, and urinary NaCl excretion rate. The effects of nebivolol on GFR were prevented by N -monomethyl-L-arginine, a nonselective inhibitor of nitric oxde synthase (NOS).
Nebivolol also increased renal nitric oxide (NO) excretion by 71%, which was also prevented by N -monomethyl-L-arginine (22) . Plasma rennin activity was decreased by nebivolol (13, 22) . In the isolated rat kidney preparation, nebivolol caused a dose-dependent reduction in renal perfusion pressure indicating a reduced renal vascular resistance and an increase in NO release that was blocked by N-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor, and metergoline, a 5-hydroxytryptamine antagonist (25) . Studies (16, 17) using myograph and an NO sensor showed that nebivolol dilated mouse renal arteries and increased NO release. Nebivolol also dilated rat renal artery rings that were preconstricted with KCl and phenylephrine; this effect was inhibited by L-NAME (47) . With the use of [ 3 H]inulin space determination to estimate contraction and relaxation of renal glomerular vasculature, nebivolol induced relaxation of the renal glomerular microvasculature through ATP efflux with consequent stimulation of P2Y-purinoceptor-mediated NO release from glomerular endothelial cells (26) . Nebivolol has also been shown to increase endothelial nitric oxide synthase (eNOS) expression and activity in various tissues (9, 30, 45, 48) .
Although it is recognized that NO is involved, the renal vasodilator mechanism of nebivolol has not been delineated. In other tissues, endothelial ␤ 3 -adrenoreceptors (7, 8, 20, 27, 33, 34, 36, 42, 43) , endothelial ␤ 2 -adrenoreceptors (2, 17, 35) , P2Y receptors (26) , and Ca 2ϩ -activated K ϩ channels (17) have been implicated in mediating its vasodilating properties. However, the effects of nebivolol on afferent and efferent arteriolar vascular tone have not been established. The present study was performed to determine the magnitude of the juxtamedullary afferent and efferent arteriolar responses to nebivolol and the roles of NOS and sGC in mediating nebivolol-induced vasodilatory responses in afferent arterioles. The detailed studies were focused on afferent arterioles as the model system to evaluate the hypothesis that nebivolol induces vasodilation of renal afferent arterioles of juxtamedullary nephron via an NOS/NO/sGC/cGMP pathway. We also tested the hypothesis that the afferent arteriolar vasodilation effect may be mediated through the release of NO by activation of NOS via a ␤ 3 -adrenoceptor dependent mechanism. While ␤ 3 -adrenoreceptor mRNA has been shown in the heart and peripheral vasculature (8, 36, 42) and the kidney (31, 50) , there is no report on the localization of ␤ 3 -adrenoreceptors in the renal microvasculature. Accordingly, immunohistochemical studies were performed to localize ␤ 3 -adrenoceptors in the kidney.
MATERIALS AND METHODS
The experimental protocols and procedures were approved by the Tulane University Institutional Animal Care and Use Committee.
Videomicroscopic measurements of afferent and efferent arteriolar diameters were performed on the isolated blood-perfused juxtamedullary nephron preparation as previously described (10, 11) . Briefly, each experiment used one male Sprague-Dawley rat (Charles River Laboratories, Wilmington, MA), weighing 370 -410 g, serving as blood donor and kidney donor. Blood was collected via the carotid arterial cannula and centrifuged and filtered to separate the plasma and cellular fractions. This reconstituted blood was pressurized with a 95% O 2-5% CO2 gas mixture. The right kidney was perfused through a cannula inserted in the superior mesenteric artery and advanced to the right renal artery. The perfusate was a Tyrode solution (pH 7.4) containing 5.1% BSA and a mixture of L-amino acids that was pressurized with a 95% O 2-5% CO2 gas mixture. The kidney was excised and sectioned longitudinally, retaining the papilla intact with the perfused dorsal two-thirds of the organ. Overlying tissue was removed to expose glomeruli and related vasculature of the juxtamedullary nephrons. The branches of renal artery were ligated to increase the perfusion pressure. After the dissection was completed, the Tyrode perfusate was replaced with the reconstituted blood. Renal perfusion pressure was set at 100 mmHg. The inner cortical surface of the kidney was continuously superfused with a warmed (37°C) Tyrode solution containing 1% BSA. The tissue was transilluminated and video images of the microvessels were evaluated with a microscope (Nikon) equipped with a water-immersion objective (ϫ40) and transferred by a Newvicon camera (model NC-67M; Dage-MTI, Michigan City, IN) through an image enhancer (model MFJ-1452; MFJ Enterprises, Starkville, MS) to a video monitor and a computer. Arteriolar inside diameters were measured at 30-s intervals using a calibrated digital image-shearing monitor (Instrumentation for Physiology and Medicine, San Diego, CA). Treatments were administered by superfusing the tissue with a Tyrode solution containing the agent to be tested or the vehicle solution.
Chemicals. The following agents used in this study: Experimental protocols. For each experiment, a single afferent or efferent arteriole from one rat kidney that showed adequate blood flow was selected for study. The arteriole was visualized and superfused with solutions containing the agents to be tested. Nebivolol was added to the superfusate at concentration varying from 1 nM to 100 M. In clinical studies, plasma levels of nebivolol in patients treated with a single dose of 10 mg were ϳ100 nM. While our effective concentrations were slightly higher, higher does are sometimes needed for in vitro studies. When the superfusate is bathed over the tissues, it mixes with the interstitial fluid and also has to diffuse to its site of action so that the effective concentration at that point may be lower. Nebivolol was superfused alone or after treatment with L-NNA, a NOS inhibitor, after treatment with ODQ, a selective inhibitor of NO-sensitive guanylyl cyclase, after treatment with metoprolol, a selective ␤1-adrenergic blocker, after treatment with butoxamine, a selective ␤2-adrenergic blocker, and after treatment with SR 59230A, a selective ␤3-adrenergic blocker. After a 15-to 20-min equilibration period, an experimental protocol was initiated consisting of consecutive 5-to 15-min treatment period for one dose based on the stabilization of vessel tone. Steady-state diameter determinations were calculated during the final 5 min of each treatment period at a perfusion pressure of 100 mmHg. The first experimental protocol was performed to determine the dose-response relationships for nebivolol. Afferent or efferent arteriolar inside diameters were measured during sequential exposure of the vessel to superfusate solutions containing 1) control vehicle, and 2) nebivolol at concentrations of 0.001, 0.01, 0.1, 1, 10, and 100 mol/l. A second series of experiments was performed to determine the effects of NOS inhibition by L-NNA on the nebivololmediated vasodilation of afferent arterioles. Afferent arteriolar inside diameters were measured during sequential exposure of the kidney to the following superfusate solutions:
by nebivolol at 1, 10, and 100 mol/l (the effective doses based on dose response experiments); 3) i) control vehicle, ii) 1,000 mol/l L-NNA; and 4) i) control vehicle, ii) 1,000 mol/l L-NNA followed by nebivolol was repeated at 1, 10, and 100 mol/l. A third series of experiments was performed to determine the effects of soluble guanylate cyclase inhibition by ODQ on the nebivolol mediated vasodilation of afferent arterioles. Afferent arteriolar inside diameters were measured during sequential exposure of the kidney to the following superfusate solutions: 1) i) control vehicle, ii) 10 mol/l ODQ; and 2) i) control vehicle, ii) 10 mol/l ODQ followed by nebivolol at 1, 10, and 100 mol/l. A fourth series of experiments was performed to determine the direct effects of different ␤1-adrenergic receptor blocker and also to test the afferent arteriolar responses to nebivolol under conditions of ␤1-adrenergic receptor blockade. Afferent arteriolar inside diameters were measured during sequential exposure of the kidney to the following superfusate solutions: 1) control vehicle; 2) metoprolol at concentrations of 1.25, 2.5, 5, 10, 20, 40, and 80 mol/l; 3) i) control vehicle, ii) 20 or 50 mol/l metoprolol; and 4) i) control vehicle, ii) addition of 20 or 50 mol/l metoprolol followed by nebivolol at 1, 10, and 100 mol/l. A fifth series of experiments was performed to determine the effects of ␤3-adrenergic receptor inhibition with SR 59230A and ␤ 2-adrenergic receptor inhibition with butoxamine on the nebivolol mediated vasodilation of afferent arterioles. Afferent arteriolar inside diameters were measured during sequential exposure of the kidney to the following superfusate solutions: 1) i) control vehicle, ii) 100 mol/l nebivolol; 2) i) control vehicle, ii) 100 mol/l nebivolol plus 2.5 or 5M SR 59230A; 3) i) control vehicle, ii) 100 mol/l nebivolol; and 4) i) control vehicle, ii) 100 mol/l nebivolol plus 10 or 100 M butoxamine.
Immunohistochemical studies were performed as previously described (19) . Briefly, rat kidneys were perfused and fixed with 4% paraformaldehyde and zinc-saturated formalin. Then, paraffin-embedded kidney sections (3 m) were processed by immunoperoxidase technique by sequential incubations with a monoclonal rabbit anti-␤3-adrenergic receptor primary antibody (cat. no. orb15066; Biobyrt, Cambridge, UK) at a 1:200 dilution for 2 h, anti-rabbit secondary antibody, and detection with DAB on methyl green used as counterstain (cat. no. H-3402; Vector Laboratories, Burlingame, CA). For dual color immunostaining, the kidney sections were sequentially incubated at room temperature for additional 30 min with blocking serum followed by 60-min incubation with a mouse smooth muscle actin (SMA) antibody (code no. M0851; DakoCytomation, Carpinteria, CA) using a rabbit/mouse EnVision G2 doublestain system kit (code no. K5361; DakoCytomation). In this case, the detection for ␤3-adrenergic receptor was performed using DAB-nickel chloride (cat. no. SK-4100; Vector Laboratories), which provides a greyblack chromogen, and SMA was detected with Permanent Red (DakoCytomation), which provides a red chromogen. The specificity of immunostaining was determined by the omission of the primary antibody and substitution with normal horse serum.
Statistical analysis. All data are reported as means Ϯ SE. Data were analyzed by two-way ANOVA or one-way ANOVA, followed by a Bonferroni's multiple-comparison post hoc test. Values of P Ͻ 0.05 were considered statistically significant. Figure 1 illustrates the effects of nebivolol on afferent and efferent arteriolar diameters. In response to superfusion with nebivolol at concentrations of 0.1, 1, 10, and 100 mol/l, afferent arteriolar diameters 1) increased significantly from 16.8 Ϯ 0.2 to 17.5 Ϯ 0.2, 18.5 Ϯ 0.3, 19.4 Ϯ 0.6, and 20.0 Ϯ 0.7 m, respectively, with an average maximum increase of 18.9 Ϯ 3.0% at the highest dose ( n ϭ 6; P Ͻ 0.01). Likewise, efferent arteriolar diameters 2) increased significantly from 17.6 Ϯ .0.2 to 17.9 Ϯ 0.3, 18.7 Ϯ 0.3, 19.9 Ϯ 0.4, and 20.4 Ϯ 0.4 m (15.8 Ϯ 1.8%; n ϭ 7; P Ͻ 0.01 vs. baseline). No significant changes were observed at concentrations of 0.001 and 0.01 mol/l. Because afferent and efferent arterioles responded similarly to nebivolol, we focused our more detailed studies using juxtamedulllary nephron afferent arterioles as our model system. Figure 2 shows the effects of nebivolol during superfusion with L-NNA. Pretreatment with L-NNA decreased afferent arteriolar diameter significantly from 17.7 Ϯ 0.3 to 14.9 Ϯ 0.3 m (Ϫ16.1 Ϯ 1.4%; n ϭ 8; P Ͻ 0.01) with a concentration of 100 mol/l and from 17.5 Ϯ 0.2 to 13.7 Ϯ 0.4 m (Ϫ22.0 Ϯ 2.2%; n ϭ 6; P Ͻ 0.01) with a concentration of 1,000 mol/l. In the presence of L-NNA at a concentration of 100 mol/l, the vasodilator responses to superfusion with nebivolol at concentrations of 1, 10, and 100 mol/l were markedly attenuated with afferent arteriolar diameter increasing from 14.9 Ϯ 0.3 to 15.3 Ϯ 0.4, 15.6 Ϯ 0.4, and 16.3 Ϯ 0.4 m. In the presence of L-NNA at a concentration of 1,000 mol/l, which has been shown to cause complete blockade of acetylcholine-induced vasodilation (37), the responses to superfusion with nebivolol were prevented with no significant increases in afferent arteriolar diameter at even the highest does of nebivolol used (2.0 Ϯ 0.2%; n ϭ 6; P Ͼ 0.05 vs. L-NNA group). Thus nebivolol-induced vasodilation was prevented by complete inhibition of NOS.
RESULTS

Effects of nebivolol on renal afferent and efferent arterioles.
Effects of NOS inhibition with L-NNA on nebivolol-induced vasodilation of afferent arterioles.
Effects of sGC inhibition with ODQ on the nebivolol mediated vasodilation of afferent arterioles. As shown in Fig. 3 , pretreatment with ODQ at a concentration of 10 mol/l decreased afferent arteriolar diameter from 16.9 Ϯ 0.3 to 14.2 Ϯ 0.5 m (Ϫ16.5 Ϯ 1.9%; n ϭ 5; P Ͻ 0.01). In the presence of ODQ, superfusion with nebivolol at concentrations up to 100 mol/l did not elicit perceptible changes in afferent arteriolar diameter (from 14.2 Ϯ 0.5 to 14.5 Ϯ 0.5 m; 2.4 Ϯ 0.6%; n ϭ Effects of nebivolol on metoprolol pretreated renal afferent arterioles. Figure 4 shows the effects of nebivolol on afferent arterioles treated with metoprolol. 1) We first determined that superfusion with metoprolol up to 80 mol/l did not caused perceptible changes in afferent arteriolar diameter (1.2 Ϯ 0.2%; n ϭ 4) demonstrating that direct ␤ 1 -receptor blockade does not elicit afferent arteriolar vasodilation. 
Effects of SR 59230A and butoxamine on nebivolol-induced vasodilation in renal afferent arterioles.
Nebivolol at a concentration of 100 mol/l alone increased afferent arteriolar diameters significantly from 16.9 Ϯ 0.2 to 19.7 Ϯ 0.3 m (16.0 Ϯ 1.6%; n ϭ 6; P Ͻ 0.01). This effect was markedly attenuated by SR 59230A. When nebivolol (100 mol/l) and SR 59230A (2.5 or 5.0 mol/l) were superfused together, the afferent arteriolar vasodilation was attenuated with diameter increasing to 18.0 Ϯ 0.2 and 17.8 Ϯ 0.2 m, respectively (n ϭ 6; P Ͻ 0.05 vs. control condition; P Ͻ 0.01 vs nebivolol alone; Fig. 5A ). However, butoxamine failed to block the nebivololinduced vasodilation; superfusion with nebivolol (100 mol/l) plus butoxamine (100 mol/l) only slightly blunted the afferent arteriolar vasodilation (Ϫ3.0 Ϯ 0.2%; n ϭ 4; P Ͼ 0.05 vs. nebivolol alone; P Ͻ 0.01 vs. control condition; Fig. 5B ). Thus only blockade of ␤ 3 -adrenergic receptors with SR 59230A markedly reduced the nebivolol-induced dilation of afferent arterioles.
Immunohistochemical localization of ␤ 3 -adrenergic receptors. A monoclonal antibody to the ␤ 3 -adrenergic receptors was utilized to localize ␤ 3 -adrenergic receptors in the kidney. As Fig. 5 . Effects of SR 59230A and butoxamine on nebivolol-induced vasodilation in renal afferent arterioles. Nebivolol (Neb) at 100 mol/l alone increased afferent arteriolar diameters significantly (A and B). This effect was markedly attenuated by combined treatment with SR 59230A (SR; n ϭ 6; P Ͻ 0.01; A) and appeared to be slightly blunted by butoxamine (BT; n ϭ 4; B). Values are means Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01 vs control condition; ##P Ͻ 0.01 vs nebivolol alone at renal perfusion pressure of 100 mmHg. (A and B) . However, after pretreatment with metoprolol, superfusion with nebivolol markedly dilated afferent arteriolar diameters (n ϭ 6; P Ͻ 0.01; B). Values are means Ϯ SE. **P Ͻ 0.01 vs control condition at renal perfusion pressure of 100 mmHg. illustrated in Fig. 6 , the ␤ 3 -receptor-specific immunoexpression was observed in the endothelial cells (brown chromogen on methyl green counsterstain) of renal vasculature (Fig. 6A ) and glomerular capillaries (Fig. 6B) . Importantly, in glomerular arterioles (Fig. 6, C and D) without the use of counterstain, the colocalization with SMA (chromogen red), a positive marker for smooth muscle cells, indicated that the ␤ 3 -receptor (grey-black) is immunoexpressed by the endothelial cells of the afferent arterioles (Fig. 6C) and efferent arterioles (Fig. 6D) .
DISCUSSION
Nebivolol is a recently developed, third-generation ␤-adrenoceptor antagonist characterized by combining highly selective ␤ 1 -adrenergic receptor antagonism with NO-dependant vasodilatory activity and reactive oxygen species scavenging effects (15) . More recently, increased attention has been focused on its pharmacological roles and cellular mechanisms. In this study, we demonstrate that nebivolol elicits marked dilation of both afferent and efferent arterioles. These findings are consistent with evidence obtained from whole kidney studies showing that nebivolol increased renal plasma flow (22, 25) , reduced renal perfusion pressure (22) , and dilated renal arteries (16, 17, 47) . At a dose of 1 mg/kg, estimated renal plasma flow increased significantly by 19%, while GFR increased 14% at this dose and 22% at 2 mg/kg. The associated increases in urine flow and sodium excretion were substantial and occurred at even lower dose. However, the in vivo effects are likely due to a combination of effects including the actions of ␤ 1 -adrenergic blockade to inhibit sympathetic-mediated stimulation of renin release. This would decrease internal angiotensin II levels and contribute to the overall renal vasodilation (22) . These combinated actions may also contribute to differential effects on the afferent and efferent arterioles. Vasodilator effects in other tissues include rat and mouse coronary microarteries (8), canine coronary, carotid and pulmonary arteries (14, 24, 41) , rat aorta, small mesenteric arteries (1, 7, 38, 47) , and human brachial artery (6) .
The mechanism of the renal vasodilator action of nebivolol has not been ultimately defined, and the identity of the receptor and pathway mediating nebivolol's activation of eNOS leading to vasodilation remains uncertain. Several studies have suggested that nebivolol-induced NO release is likely to be mediated by ␤ 3 -adrenergic receptor stimulation (7, 8, 20, 27, 33, 34, 36, 42, 43) . Dessy et al. (8) reported that nebivolol failed to dilate aortic rings in ␤ 3 -adrenoreceptor-deficient mice and that nadolol, a selective ␤ 1-2 -adrenoreceptor blocker, did not attenuate the nebivolol-induced vasodilation in rat and human coronary microarteries indicating that the drug's vasodilator action is not via ␤ 1 -or ␤ 2 -adrenoreceptors. In contrast to the effect of ␤ 1-2 -blockade, the complete ␤ 1-2-3 -blocker bupranolol significantly inhibited the relaxation elicited by nebivolol in rat coronary microarteries supporting a role for ␤ 3 -adrenergic receptors in the NO-mediated vasodilatory effects of nebivolol (8) . However, the investigators did not use a highly selective ␤ 3 -blocker in these experiments. In endothelian-1-precontracted rat thoracic aorta rings, nebivolol induced a concentration-dependent relaxation, which was unaffected by nadolol but was significantly reduced by L-748,337, a ␤ 3 -AR antagonist (43) . A study (33) using the fluorescent probe diaminofluorescein showed that nebivolol induces a dosedependent NO production in mouse heart, but was not able to induce NO production in presence of the ␤ 3 -antagonist SR59230A further supporting a fundamental role for ␤ 3 -adrenergic receptors in cardiac NO production by nebivolol. Nebivolol activates a calcium-independent transduction pathway that implicates an increase in adenylate cyclase and phospholipase Fig. 6 . Immunolocalization of the ␤3-adrenergic receptor in the normal rat kidney. Paraffin-embedded rat perfused kidney sections (3 m) were incubated with a monoclonal rabbit anti-␤3-adrenergic receptor antibody (Biobyrt; Cambridge, UK) at 1:200 dilution for 2 h using an immunoperoxidase technique (A-D). With the use of methyl green as a counterstain (A and B) , specific brown stain (DAB) is observed in the endothelial cells of a renal arteriole (Art; A) and glomerular arterioles (Glom; B). C and D: kidney sections without counterstain using costaining with permanent red chromogen (Dako Cytomation) for smooth muscle actin (red; SMA) and grey-black chromogen with DAB-nickel chloride (Vector Laboratories) for ␤3-adrenergic receptor. C, top right: lower magnification (ϫ40) field of the selected structures despite in C showing the presence of ␤3-receptor-specific immunostaining at the endothelial cells of the glomerular afferent arteriole (AA) . D: presence of ␤3-adrenergic receptor in the endothelium of efferent arterioles (EA). All microphotographs were taken using a digital camera (DS-Fi1) and a ϫ100 magnification-oil immersion objective (Nikon Eclipse 50i).
A2 activity. The ␤ 1 -or ␤ 2 -adrenoreceptor antagonists do not inhibit the action of nebivolol. However, its action on cyclic AMP production is inhibited by bupranolol, a ␤ 1-3 -adrenoreceptor antagonist, and S-(Ϫ)-cyanopindolol, a selective ␤ 3 -adrenoreceptor antagonist, suggesting that ␤ 3 -adrenoreceptor is involved in nebivolol vasodilator properties (20) . However, some studies suggest that the cellular mechanisms of the vasodilator effect of nebivolol may also involve activation of the endothelial ␤ 2 -adrenoceptors (2, 17, 35) , Ca 2ϩ -activated K ϩ channels (17) and P2Y-purinoceptor (26) . It has also been suggested that while the vasodilation induced by nebivolol is mediated by endothelium-derived NO, ␤ 2, ␤ 3 -adrenoceptors, 5-hydroxytryptamine receptors (4), and K ϩ channels (47) are not involved in the nebivolol-induced vasodilation. These studies indicate the need for evaluating tissue specific responses thus necessitating our direct studies on the renal microvasculature.
It is well established that NO is formed by NOS. NOS converts L-arginine to citrulline and NO. NO activates the enzyme sGC to produce the second messenger cGMP, which subsequently activates protein kinase G and leads to vasodilation (18, 44) . eNOS is the most abundant NOS isoform in the cardiovascular system. eNOS activity is affected by a variety of modifications, such as phosphorylation and acylation, by its cellular localization, and by protein-protein interactions (18, 21) . The mechanisms of signal transduction leading to NOS activation are not yet fully delineated. Previous studies (18, 21) suggest that the major factors stimulating nitric oxide synthases are shear stress, serine/threonine protein kinase Akt/PKB, phosphorylated Akt and Ca 2ϩ -calmodulin. In the present study, we demonstrated that in response to NOS blockade with L-NNA afferent arteriolar diameter decreased significantly as reported previously (12) . Nebivolol-induced afferent arteriolar vasodilation was markedly attenuated by pretreatment with L-NNA (100 M) and prevented by pretreatment with L-NNA (1,000 M), indicating that nebivolol vasodilates renal afferent arterioles via NOS-NO pathway. These results agree with previous studies showing NO-dependent vasodilator effects of nebivolol in other tissues (17, 25, 35, 36, 47) . Nebivolol elicited some vasodilation under condition of incomplete NOS blockade with the lower dose of L-NNA, suggesting that with incomplete NOS suppression nebivolol may stimulate NOS, thereby increasing the availability of NO in the endothelium and smooth muscle to restore endothelial function. While we focused our detailed studies on afferent arterioles because of their greater availability, it is likely that similar mechanisms are responsible for the efferent responses as well. It has already been demonstrated that L-NNA elicits similar vasoconstriction responses in efferent arterioles (12) .
In further studies, the vasodilator effects of nebivolol were prevented by ODQ, indicating complete blockade of nebivololinduced vasodilation by sGC inhibition, which further confirmed that the endothelial localization of the target mechanism activated by nebivolol is NOS and the NOS-NO-sGC-cGMP pathway mediates the nebivolol-inducded vasodilation. Nebivolol may activate NOS to produce NO, which leads to activation of sGC and increases in cGMP. These findings are in accordance with evidence obtained from cellular studies on NOS showing that nebivolol induces eNOS activation by a translocation of the enzyme, as well as serine 1177 -phosphorylation (30) and Akt/protein kinase B (3, 30) ; by dephosphorylation of Thr 495 -eNOS (8); and through the phosphatidylinositol 3-kinase/Akt pathway (28), inducing phosphorylation of eNOS (32) . Nebivolol increases eNOS expression and activity in renal artery (17, 45, 48) and renal NO release in the rat kidney, which was also prevented by NOS inhibition (22, 25) .
To determine the role of ␤ 1 -adrenoreceptor activation in the afferent arteriolar responses to nebivolol and distinguish the vasodilatory action of nebivolol from other ␤-adrenergic blockers that selectively inhibit ␤ 1 -receptors, we tested the effect of nebivolol in the presence of ␤ 1 -blockade with metoprolol. The absence of changes with metoprolol and the failure of metoprolol to prevent the response to nebivolol indicate that the vasodilation is mediated via a mechanism not directly involving blockade of ␤ 1 -adrenergic receptors, suggesting a novel pathway mediating the nebivolol-inducded vasodilation. Further studies showed that ␤ 2 -adrenoceptors blockade with butoxamine only slightly blunted the vasodilatory effect of nebivolol, suggesting a minor possible role mediated by ␤ 2 -adrenoceptors. In contrast, nebivolol-induced afferent arteriolar vasodilation was markedly attenuated after blocking ␤ 3 -adrenoceptors with SR 59230A indicating an agonist effect of nebivolol on endothelial ␤ 3 -adrenergic receptors, thus suggesting that the vasodilator effect of nebivolol is mediated through the release of NO via a ␤ 3 -adrenoceptor-dependent mechanism. These results are supported further by our current immunohistochemical data revealing the presence of ␤ 3 -adrenoceptors on endothelial cells of renal arterioles and glomerular capillaries, suggesting their functional role to activate ␤ 3 -adrenoceptors and NOS and elicit renal vasodilation. These findings fit well with functional studies in coronary arteries and other tissues showing that the vasodilator effects of nebivolol is mediated via activation of endothelial ␤ 3 -adrenergic receptors (7, 8, 20, 27, 43, 33) and molecular studies showing that ␤ 3 -adrenoceptors are expressed in the kidney (31, 50) and the endothelial cells of aorta (3) and human coronary resistance arteries (8) . These results have important implications for the pathways involved in adrenergic modulation of eNOS pathways in the vascular wall (28) . These findings provide mechanistic insights suggesting that ␤ 3 -adrenergic receptors may respond to excessive renal sympathetic nerve activation by providing a counteracting renal protective influence to prevent excessive renal vasoconstriction during states of elevated sympathetic activity (8, 34, 36, 42) .
In summary, nebivolol markedly vasodilates both renal afferent and efferent arterioles of juxtamedullary nephrons. The afferent arteriolar responses are due to a mechanism not directly involving blockade of ␤ 1 -adrenergic receptors but predominantly mediated through the release of NO via NOS/NO/ sGC/cGMP-dependent mechanism involving activation of ␤ 3 -adrenergic receptors and NOS, thus revealing the presence and action of ␤ 3 -adrenergic receptors as potential regulators of renal hemodynamics during states of high sympathetic activity.
The effects of nebivolol to vasodilate renal afferent and efferent arterioles are of potential clinical relevance for conditions related to treatment of hypertension and associated cardiovascular disorders where there is evidence of renal vasoconstriction. The renal microvasculature plays a crucial role in the control of blood pressure. NO-mediated renal vasodilation is impaired in hypertension and diabetes due to a decrease NO bioavailability, NOS activity, and NO-cGMP signaling. The present study provides direct data demonstrating that nebivolol elicits vasodilation of the renal microvasculature and suggests that the major pathway is via ␤ 3 -adrenergic receptor and NOS activation. Nebivolol-induced renal vasodilation could be of benefit in the treatment of hypertension and associated cardiovascular disorders associated with hypertension and endothelial dysfunction.
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